# The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage

> **NCT00991198** · PHASE2 · COMPLETED · sponsor: **Aria Aesthetics Inc.** · enrollment: 49 (actual)

## Conditions studied

- Rosacea
- Acne Vulgaris
- Atopic Dermatitis
- Seborrheic Dermatitis

## Interventions

- **DRUG:** Topical oxygen
- **DRUG:** Topical oxygen
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00991198
- **Lead sponsor:** Aria Aesthetics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00991198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00991198, "The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00991198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*